[Rosacea: New data for better care]

Ann Dermatol Venereol. Aug-Sep 2017;144(8-9):508-517. doi: 10.1016/j.annder.2017.06.010. Epub 2017 Jul 17.
[Article in French]


In the last 10 years, numerous studies have been published that throw new light on rosacea, in all areas of the disease. This overview summarises all the key developments, based on the indexed bibliography appearing in Medline between 2007 and 2017. Recent epidemiological data show that the prevalence of the disease is doubtless greater than estimated hitherto (more than 10% of adults in some countries) and that we should not overlook rosacea in subjects with skin phototypes V or VI, a condition that exists on all continents. A new classification of rosacea by phenotype comprising major and minor signs has been put forward; it provides a more rational approach to suitable management based upon symptoms, the severity of which may be graded into 5 classes. The treatments with the best-demonstrated efficacy (updated Cochrane study) are topical metronidazole, azelaic acid and ivermectin, and oral doxycycline; isotretinoin is effective against resistant forms but is off-label. In ocular rosacea, the reference treatment is doxycycline in combination with topical therapy of the eyelids. The physiopathology is complex and involves several factors: vascular (vasodilatation, vascular growth factors), neurovascular (hypersensitivity, neuropathic pain, neuropeptides), infectious (Demodex folliculorum and its microbiota) and inflammatory (abnormal production of pro-inflammatory peptides of the innate immune system). In addition, there is a genetic predisposition as demonstrated by the weight of familial history and comparison of homozygous and heterozygous twins. There is also activation of several genes involved in immunity, inflammation and lipid metabolism; the theory of hydrolipid film anomalies has been posited once more. There has thus been a tremendous leap forward in the field of rosacea research, with therapeutic progress and improved understanding of the underlying mechanisms, which should enable the future development of more targeted treatments as well as global management of this disease, which has major social and emotional consequences on the life of patients.

Keywords: Demodex; Epidemiology; Immunité innée; Innate immunity; Rosacea; Rosacée; Thérapeutique; Treatment; Épidémiologie.

Publication types

  • Review

MeSH terms

  • Administration, Cutaneous
  • Administration, Oral
  • Adult
  • Anti-Bacterial Agents / administration & dosage*
  • Dermatologic Agents / administration & dosage*
  • Dicarboxylic Acids / administration & dosage*
  • Doxycycline / administration & dosage*
  • Drug Combinations
  • Female
  • France / epidemiology
  • Humans
  • Isotretinoin / administration & dosage*
  • Ivermectin / administration & dosage*
  • Metronidazole / administration & dosage*
  • Phenotype
  • Prevalence
  • Quality of Life
  • Rosacea / diagnosis
  • Rosacea / epidemiology
  • Rosacea / genetics
  • Rosacea / therapy*
  • Skin Cream / administration & dosage
  • Treatment Outcome


  • Anti-Bacterial Agents
  • Dermatologic Agents
  • Dicarboxylic Acids
  • Drug Combinations
  • Metronidazole
  • Ivermectin
  • Isotretinoin
  • azelaic acid
  • Doxycycline